Caring for Patients with Nasal Polyps in 2023: When to Consider a Biologic or Surgery?
August 24, 2023
October 24, 2024
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)..
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and and Sanofi.
Date of Release/Expiration
This activity was released on August 24th, 2023 and is valid until October 24, 2024. Requests for credit must be made no later than October 24th, 2024.
- Physicians - maximum of 1.5 AMA PRA Category 1 Credits™
The intended audience for this program is ENTs, allergists, immunologists, specialty nurse practitioners and PAs, and other clinicians involved in the management of patients with nasal polyps (NPs).
In a recent outcomes survey of patients with nasal polyps (NPs), 88% responded that their treatment journey had been extremely burdensome and that lack of communication with their care team was a barrier to proper diagnoses or changes in therapeutic approaches. With increased awareness of newer, more effective treatments, frontline clinicians who manage NPs and chronic rhinosinusitis with nasal polyposis (CRSwNP) can help alleviate patients’ disease burden related to inadequate symptom control and recurrent disease.
Join an expert panel of allergy and ENT specialists to review the latest understanding of NPs and CRSwNP, including severe NPs and those at high risk for recurrence. Panelists will clarify the place of functional endoscopic sinus surgery (FESS) and biologic agents in the treatment of CRSwNP. After participating in the education, clinician participants will recognize biologics available to treat NPs and understand which patient characteristics justify their use. Participating allergists ENTs will also be prepared to collaborate in the care of patients with NPs and include them in effective, shared decisions about treatment.
After completing this activity, the participant should be better able to:
- Summarize the burden of disease and treatment for people with NPs, with a focus on outcomes that matter to patients, such as ability to smell, sleep, and be productive
- Describe the T2 inflammatory relationships between NPs and common comorbidities, such as asthma, aspirin-exacerbated respiratory disease (AERD), and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD)
- Explain how enhanced knowledge of NP endotypes and T2 inflammatory pathways can guide treatment decisions
- Review recent recommendations for the management of NPs with surgery and monoclonal antibodies, especially as they apply to the management of uncontrolled, severe NPs
Stella Lee, MD
Director of the Brigham Sinus Center
Brigham and Women's Hospital
Kathleen Buchheit, MD
Assistant Professor of Medicine
Brigham and Women's Hospital
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Education
Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Instruction for Participaton and Credit:
Estimated Time to Complete
This activity should take approximately 90 minutes to complete.
Instruction to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at [email protected].
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”